After 62 years of regulating immunity, dexamethasone meets COVID-19.
Publication
, Journal Article
Cain, DW; Cidlowski, JA
Published in: Nat Rev Immunol
October 2020
Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Immunol
DOI
EISSN
1474-1741
Publication Date
October 2020
Volume
20
Issue
10
Start / End Page
587 / 588
Location
England
Related Subject Headings
- Time Factors
- Severity of Illness Index
- SARS-CoV-2
- Receptors, Glucocorticoid
- Randomized Controlled Trials as Topic
- Pneumonia, Viral
- Pandemics
- Immunosuppressive Agents
- Immunology
- Immunity, Innate
Citation
APA
Chicago
ICMJE
MLA
NLM
Cain, D. W., & Cidlowski, J. A. (2020). After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol, 20(10), 587–588. https://doi.org/10.1038/s41577-020-00421-x
Cain, Derek W., and John A. Cidlowski. “After 62 years of regulating immunity, dexamethasone meets COVID-19.” Nat Rev Immunol 20, no. 10 (October 2020): 587–88. https://doi.org/10.1038/s41577-020-00421-x.
Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol. 2020 Oct;20(10):587–8.
Cain, Derek W., and John A. Cidlowski. “After 62 years of regulating immunity, dexamethasone meets COVID-19.” Nat Rev Immunol, vol. 20, no. 10, Oct. 2020, pp. 587–88. Pubmed, doi:10.1038/s41577-020-00421-x.
Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol. 2020 Oct;20(10):587–588.
Published In
Nat Rev Immunol
DOI
EISSN
1474-1741
Publication Date
October 2020
Volume
20
Issue
10
Start / End Page
587 / 588
Location
England
Related Subject Headings
- Time Factors
- Severity of Illness Index
- SARS-CoV-2
- Receptors, Glucocorticoid
- Randomized Controlled Trials as Topic
- Pneumonia, Viral
- Pandemics
- Immunosuppressive Agents
- Immunology
- Immunity, Innate